is semaglutide or tirzepatide better for inflammation Ozempic, Mounjaro, Zepbound | Do they reduce Inflammation? The weight-loss-independent hepatoprotective benefits of

Dual and multi-receptor obesity peptide comparison (June 2026) Peptide Survodutide (BI 456906) Receptor targets GLP-1 + Glucagon Top reported weight loss 16.6% (Phase 3 SYNCHRONIZE-1, 76 weeks) Route Subcutaneous, once weekly FDA status Investigational Peptide Retatrutide Receptor targets GLP-1 + GIP + Glucagon (triple) Top reported weight loss 24.2% (Phase 2, 48 weeks) Route Subcutaneous, once weekly FDA status Investigational Peptide Tirzepatide (Mounjaro / Zepbound) Receptor targets GLP-1 + GIP Top reported weight loss 20.9% (SURMOUNT-1, 72 weeks) Route Subcutaneous, once weekly FDA status FDA-approved (T2D and obesity) Peptide Semaglutide (Ozempic / Wegovy / Rybelsus) Receptor targets GLP-1 only Top reported weight loss 14.9% (STEP 1, 68 weeks) Route Subcutaneous, once weekly (oral Rybelsus daily) FDA status FDA-approved (T2D and obesity) Peptide CagriSema (cagrilintide + semaglutide) Receptor targets GLP-1 + Amylin Top reported weight loss 22.7% (REDEFINE-1 Phase 3) Route Subcutaneous, once weekly FDA status Investigational Numbers are from each peptide's primary trial

The potential risks include digestive discomfort, gas, and bloating. They can also reduce the absorption of certain medications like lithium, certain antidepressants, digoxin, diabetes medications, bile acid sequestrants, and carbamazepine

Additionally, the average level of HbA1c was also shown to significantly decrease when semaglutide was administered via subcutaneous injection rather than orally [3]

Chemotherapy agents (oral capecitabine, temozolomide)

The lag behind the trigger often causes confusion

The authors reported 11 of 12 patients improved in pain